Document Type: Review Article

Authors

1 FACULTY OF PHARMACY,DIT UNIVERSITY, DEHRADUN, UTTARAKHAND,INDIA

2 FACULTY OF PHARMACY, DIT UNIVERSITY, DEHRADUN, UTTARAKHAND, INDIA

Abstract

Delivery of API molecules to the brain is a challenging task. The main aim of this review is to present ocular route as a powerful region and focus on the various Nano-formulations. Various efforts in ocular drug delivery have been made to improve the bioavailability and to prolong the residence time of drugs applied topically onto the eye. Poor bioavailability of drugs from ocular dosage form is mainly due to the tear production, non-productive absorption, transient residence time, and impermeability of corneal epithelium. Though the topical and localized application are still an acceptable and preferred way to achieve therapeutic level of drugs used to treat ocular disorders but the primitive ophthalmic solution, suspension, and ointment dosage form are no longer sufficient to combat various ocular diseases. This article reviews the constraints with conventional ocular therapy and explores various novel approaches, in general, to improve ocular bioavailability of the drugs, advantages of vesicular approach over these and the future challenges to render the vesicular system more effective.

Graphical Abstract

Keywords

Main Subjects

1. Pathak S, Chopra H Int J of Phar and Bio Sci :2230-7605.

2. Kompella1 UB, Kadam RS, Lee VHL (2010) NIH 1 : 435-56.

3. Thakur S, Sharma PK, Malviya R Annals of Pharmaco and Pharmaceut 2:1043.

4. Rupenthala ID et al (2011) International Journal of Pharmaceutics 411:69-77.

5. Alonso MJ et al (2010) Advanced Drug Delivery Reviews 62:100-17.

6. Khokhar P, Shukla V (2014) International Journal of Pharma Research & Review 3:29-41.

7. Ankit K et al (2011) European Journal of applied sciences 3: 86-92.

8. Costa VP, Marcelo LO, Freitas FR, Raul CM (2012) Pharmaceutics 4:252-275.

9. Morrison PW, Khutoryanskiy VV (2014) Ther Deliv 5: 297-315.

10. Washington N, Washington WC, Wilson CG (2001) Pharmaceutics: CRC Press: Boca Raton, Florida.

11. Kaur IP et al (2004) International Journal of Pharmaceutics 269: 1-14.

12. Karthika K et al, Int J Pharm Sci 2: 1-5.

13. Smedt SCD et al (2017) Advanced Drug Delivery Reviews.

14. Tao LL et al (2017) Advanced Drug Delivery Reviews 122:31-64.

15. Tekade RK et al (2017) Journal of Controlled Release 268: 19-39.

16. Pathak S, Chopra H (2011) International Journal of Pharmacy and Biological Sciences: 2230-7605.

17. Patel PB (2010) Systematic Reviews in Pharmacy 1.

18. Weisheng Guo et al (2017) Acta Pharmaceutica Sinica B 7: 281-291.

19. Yavuz B et al (2012) The Scientific World Journal.

20. Elisa JC, Antonio C, Joao M, António FA (2017) Nanomedicine: Nanotechnology, Biology, and Medicine 13: 2101-13.

21. Patel A et al (2013) World J Pharmacol 2: 47-64.

22. Madni A et al (2017) International Journal of Pharmaceutics 530: 326-45.

23. Costa VP, Marcelo LO, Freitas FR, Raul CM (2012) Pharmaceutics 2012 : 252-275.

24. Tekade RK et al (2017) Novel Journal of Controlled Release 268:19-39.

25. Khutoryanskiy VV et al (2017)Colloids and Surfaces B: Biointerfaces 155: 538-43.

26. Vandamme TF (2002) Prog Retin Eye Res 21:15-34.

27. Liang H et al (2008) Mol Vis 14:204-16.

28. Lang, Roehrs J, Jani R, Remington R (2009) Ophthalmic preparations: 856.

29. Attama AA, Reichi S, Muller-Goymann (2008) Int J Pharm 355: 307-13.

30. Muller RH et al (2008) Eur J Pharm Biopharm 68:535-544.

31. Fialho SL, Da Silva-Cunha A (2004) Clin Exp Ophthalmol 32:626-32.

32. Garty N, Lusky M, Zalish M (1994) Invest Ophthalmol Vis Sci 35: 2175-86.

33. Civiale C et al (2009) Int J Pharm 378: 177-86.

34. Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G (2002) Biomaterials 23 : 3247-55.

35. Aggarwal D, Garg A, Kaur LP (2004) J Pharm Pharmacol 56: 1509-17.

36. Loftsson T, Fririksdottir H, Thorsdottir S, Stefansson E (1994) Int J Pharm 104: 181-184.

37. Kristinsson JK et al (1996) Invest Ophthalmol Vis Sci 37:1119-1203.

38. Bochot A, Fattai E, Gullk A, Couyarraze G, Couvreur P (1998) Pharm Res 15 :1364-69.

39. Ahmed I, Patton TF (1987) Int J Pharm 38: 9-21.

40. Vandamme TF, Brobeck L (2005) J Control Release 102: 23-38.

41. Saettone MF, Perini G, Carafa M, Santucci E, Alhaique F (1996) STP Pharma Sci 6 : 94-98.

42. Anatomy of human eye february, 2018.

43. Eye anatomy retrieved from www.valleyeyecare.org. February, 2018.

44. Evans HE, Lahunta A (2010) Guide to the dissection of the dog, 7th edn Missouri: Saunders Elsevier.